VRNA
Verona Pharma plc (VRNA) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Durability
Gross margin remains very high at 95.5%, supporting strong unit economics.
Revenue base is still small relative to valuation, with price-to-sales at 541.7x and EV/sales at 540.3x.
No fresh news or metric change indicates a new growth catalyst this month.
Profitability
Operating profitability is still thin, with EBIT margin at 2.5% and operating margin at 1.3%.
Net margin remains negative at -2.9%, and ROE is -1.6%.
Interest coverage is only 0.10x, indicating limited earnings cushion.
Financial Strength
Liquidity remains very strong, with a current ratio of 10.7x and cash ratio of 8.5x.
Net debt remains negative relative to EBITDA, indicating a net cash position.
Debt-to-equity is 0.88x, but coverage ratios remain weak.
Valuation
Valuation remains extremely stretched, with EV/sales at 540.3x and price-to-free-cash-flow at 3,936.1x.
Price-to-book is 32.9x, leaving little margin for error.
No material news or metric improvement offsets the premium valuation.
Momentum
No recent news was provided to indicate a momentum shift.
The company still shows positive operating cash flow and free cash flow, but profitability remains weak.
Without fresh catalysts, momentum remains neutral to modest.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Verona Pharma plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

